This archive report was first published on 13 August 2019.
Published on August 13, 2019, a groundbreaking vaccine to protect people against chlamydia has successfully completed its initial safety tests.
Researchers from Imperial College London compared two different formulations of the vaccine alongside a dummy or placebo jab in 35 women, with both formulations appearing to be safe.
According to Prof Robin Shattock, the lead investigator, the findings are encouraging as they show the vaccine is safe and produces the type of immune response that could potentially protect against chlamydia.
While the vaccine has shown promise, further trials are needed to determine its effectiveness and the optimal dosage.
Chlamydia remains a significant public health concern, with nearly half of all sex infections diagnosed in the UK being caused by this bacterial infection.
Experts emphasize that vaccination could offer long-lasting protection, and the next phase of testing is expected to begin within the next year or two.
Prof Shattock suggests that the vaccine could potentially be offered alongside the HPV jab, which is currently used to protect against cervical cancer.
